Race Oncology Ltd (ASX: RAC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Race Oncology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $142.80 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 164.13 million
Earnings per share -0.062
Dividend per share N/A
Year To Date Return -1.19%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Race Oncology Ltd (ASX: RAC)
    Latest News

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Share Market News

    This ASX All Ords director has bought 25,000 of his company's shares in a week

    This director made a big investment last week.

    Read more »

    A young female ASX investor sits at her desk with her fists raised in excitement as she reads about rising ASX share prices on her laptop.
    Share Gainers

    Why Cogstate, Mayne Pharma, Race Oncology, and Whitehaven Coal are charging higher

    These ASX shares are on form on Wednesday...

    Read more »

    Three rock climbers hang precariously off a steep cliff face, each connected to the other with the higher person holding on and the two below them connected by their arms and rope but not making contact with the cliff face.
    Earnings Results

    3 ASX All Ords shares tumbling lower following full-year results

    These ASX All Ords shares took a bath on Monday following earnings...

    Read more »

    A group of people in a corporate setting do a collective high five.
    Earnings Results

    Race Oncology share price leaps 5% on quarter of 'major advances'

    Quarter dominated by promising results have investors revved up...

    Read more »

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    Up 38% in a month, what's sparking the recent Race Oncology share price run-up?

    What a month it has been for Race Oncology shareholders.

    Read more »

    A man in a wheelchair stretches both arms into the air in success.
    Index investing

    ASX 200 healthcare shares provided some pain relief today. Here's why

    The healthcare sector ended Thursday as the best performer on the ASX.

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Why is the Race Oncology share price soaring 13% today?

    New trial results have excited ASX investors.

    Read more »

    Boy in business suit smiles with arms crossed and rockets attached to his back representing the rocketing BrainChip share price
    Healthcare Shares

    Why did the Race Oncology share price rocket 10% today?

    Investors view Race Oncology's latest release in a positive light.

    Read more »

    A man wearing a white coat holds his hands up and mouth open with joy.
    Healthcare Shares

    Race Oncology share price soars 16% on buyback news

    The pharmaceutical company's shares are receiving a welcome boost today.

    Read more »

    Female doctor with a mask holds out hand in a stop gesture.
    Healthcare Shares

    Why is the Race Oncology share price in a trading halt?

    Race Oncology is set to release some trial results to the market in the coming days.

    Read more »

    A woman looks distressed as she stares dramatically at her phone
    Share Market News

    5 ASX shares making unbelievable news this week

    These five ASX shares made headlines this week.

    Read more »

    Female scientist working in laboratory for Race Oncology
    Healthcare Shares

    'Compelling results': Here's why the Race Oncology (ASX:RAC) share price is rocketing 5%

    The biotech company is on the share price racetrack again today – and leading its ASX peers.

    Read more »

    Frequently Asked Questions

    No, Race Oncology does not pay dividends at this time.

    Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.

    RAC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Race Oncology Ltd

    Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.

    Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.

    The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).

    As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.

    RAC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Mar 2024 $0.87 $0.04 4.82% 171,884 $0.85 $0.88 $0.85
    01 Mar 2024 $0.83 $-0.02 -2.35% 38,783 $0.85 $0.85 $0.81
    29 Feb 2024 $0.85 $0.07 8.92% 90,361 $0.80 $0.85 $0.79
    28 Feb 2024 $0.79 $0.01 1.29% 57,081 $0.80 $0.84 $0.78
    27 Feb 2024 $0.78 $-0.02 -2.53% 58,469 $0.79 $0.79 $0.77
    26 Feb 2024 $0.79 $-0.01 -1.26% 35,094 $0.82 $0.82 $0.78
    23 Feb 2024 $0.80 $-0.01 -1.24% 64,321 $0.81 $0.84 $0.79
    22 Feb 2024 $0.81 $0.03 3.85% 107,011 $0.79 $0.85 $0.78
    21 Feb 2024 $0.78 $0.02 2.61% 30,742 $0.77 $0.78 $0.76
    20 Feb 2024 $0.77 $0.01 1.32% 39,912 $0.76 $0.78 $0.76
    19 Feb 2024 $0.76 $0.01 1.33% 69,929 $0.75 $0.78 $0.74
    16 Feb 2024 $0.75 $-0.02 -2.61% 149,361 $0.77 $0.80 $0.73
    15 Feb 2024 $0.77 $0.01 1.32% 47,969 $0.76 $0.79 $0.76
    14 Feb 2024 $0.76 $-0.05 -6.21% 147,253 $0.85 $0.85 $0.76
    13 Feb 2024 $0.81 $0.04 5.19% 252,330 $0.78 $0.86 $0.78
    12 Feb 2024 $0.77 $0.04 5.48% 50,696 $0.75 $0.80 $0.75
    09 Feb 2024 $0.73 $0.04 5.76% 305,383 $0.69 $0.80 $0.69
    08 Feb 2024 $0.70 $0.00 0.00% 78,663 $0.67 $0.70 $0.65
    07 Feb 2024 $0.70 $0.02 2.99% 56,102 $0.67 $0.70 $0.66
    06 Feb 2024 $0.67 $-0.01 -1.47% 3,807 $0.68 $0.68 $0.67
    05 Feb 2024 $0.68 $0.00 0.00% 98,992 $0.70 $0.70 $0.66

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Dec 2023 Phillip(Phil) Lynch Issued 21,457 $18,989
    Issue of options.
    04 Dec 2023 Mary Harney Issued 1,170 $1,035
    Issue of options.
    01 Dec 2023 Peter (Pete) Smith Issued 440,019 $374,016
    Issue of options.
    01 Dec 2023 Mary Harney Issued 139,516 $118,588
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Phillip(Phil) R Lynch Non-Executive Director Feb 2023
    Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an experienced executive and board director, with a background across corporate development, strategy, financial performance, marketing and governance.
    Ms Mary Harney Non-Executive Director Feb 2021
    Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company.
    Dr Peter (Pete) Smith Executive Director Jun 2023
    Dr Smith has over 30 years of experience in the pharmaceutical and biotech industry, in therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private biotechnology company Myrio Therapeutics. Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A. His undergraduate degree and PhD are from the University of Cambridge. In addition to serving as a Director of Race Oncology, he is also currently a Director of Myrio Therapeutics, MycRx Inc., Hula Therapeutics Inc. and Amala Therapeutics.
    Mr Peter Webse Company Secretary Aug 2016
    Peter Webse Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Daniel Tillett 14,014,370 8.59%
    Mr Phillip Richard Perry 6,047,694 3.71%
    Mr Mark Phillip Juan 5,652,312 3.47%
    Biosynergy Partners Pty Ltd 5,102,194 3.13%
    The Trust Company (Australia) Limited <MOF A/C> 4,450,468 2.73%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,648,807 1.62%
    Dr Daniel Tillett (ii) 2,307,925 1.42%
    Craganorig Holdings LLC 2,000,000 1.23%
    Marinella Messina 1,757,377 1.08%
    Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,600,000 0.98%
    Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,579,250 0.97%
    Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,350,000 0.83%
    Kudoss Investments Pty Ltd <Aitken Global Family A/C> 1,153,034 0.71%
    Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C> 1,080,000 0.66%
    Mr Sandor Helby 1,060,000 0.65%
    Mr Alan Giles Sauran 1,031,256 0.63%
    Biosynergy Partners Pty Ltd (ii) 1,000,000 0.61%
    Citicorp Nominees Pty Limited 856,443 0.53%
    Mr Van Quy Do 825,788 0.51%
    Mr Brian James Walker 777,777 0.48%